151 – 160 of 346
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Preclinical Characterization of 3β-(N-Acetyl l -cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
(
- Contribution to journal › Article
-
Mark
PBX3 is a putative biomarker of aggressive prostate cancer
(
- Contribution to journal › Article
-
Mark
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer : A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice
(
- Contribution to journal › Article
-
Mark
Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study
(
- Contribution to journal › Article
-
Mark
The Molecular Evolution of Castration-resistant Prostate Cancer
(
- Contribution to journal › Scientific review
-
Mark
Re : The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The prostate cancer registry : Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)
(
- Contribution to journal › Article
- 2015
-
Mark
Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial